Industry Data Insights provides industry-focused research and analytical intelligence for organizations seeking a clearer view of market performance, competitive conditions, and long-term business opportunities. Through syndicated reports, customized studies, and strategic research support, Industry Data Insights helps businesses access the information needed to evaluate markets and plan for sustainable growth. Our research covers the full market landscape, including industry structure, historical performance, current demand, value-chain developments, regional trends, customer requirements, technological change, and future growth potential. We examine the factors that influence market outcomes, including economic conditions, supply-chain dynamics, policy and regulatory developments, innovation, investment activity, and changing end-user preferences.
At Industry Data Insights, we use a research framework that brings together credible secondary sources, public and company-level information, industry publications, trade statistics, expert perspectives, and data-led market modeling. Our analysts validate key assumptions and assess multiple market variables to develop balanced, actionable conclusions for business leaders, investors, consultants, and product teams. Industry Data Insights supports a broad range of verticals, including industrial manufacturing, engineering, construction, chemicals, energy and power, healthcare, information technology, telecom, automotive, packaging, agriculture, consumer products, retail, and transportation. Each study is structured to help users understand both the immediate market environment and the longer-term forces that may influence demand and competition. From identifying high-potential segments to assessing a competitor’s position or evaluating a new geography, Industry Data Insights delivers research that is designed to be useful, relevant, and aligned with real business questions. Our goal is to turn industry data into strategic direction.
US Prostate Cancer Biomarkers Market Report 2026-2033
Us Prostate Cancer Biomarkers Market Report by Type (Genetic Biomarkers, Protein Biomarkers, Cell-based Biomarkers, Metabolomic Biomarkers), by Application (Screening and Early Detection, Diagnosis and Risk Stratification, Prognosis and Treatment Monitoring, Companion Diagnostics), by End Use (Hospitals and Diagnostic Laboratories, Academic and Research Institutes, Biopharmaceutical Companies), by United States (Northeast, Midwest, South, West) Forecast 2026-2034
US Prostate Cancer Biomarkers Market Report 2026-2033
Discover the Latest Market Insight Reports
Access in-depth insights on industries, companies, trends, and global markets. Our expertly curated reports provide the most relevant data and analysis in a condensed, easy-to-read format.
Us Prostate Cancer Biomarkers Market Report: Valuation Timeline 2025–2033
Our proprietary primary research places the U.S. prostate cancer biomarkers market at $2.20 billion in 2025, scaling to $2.49 billion in 2026 and $6.01 billion by 2033, representing a 13.5% CAGR (2026–2033). The U.S. accounts for 41.4% of the global market, reflecting its advanced diagnostic infrastructure and high screening adoption.
Us Prostate Cancer Biomarkers Market Report Market Size (In Billion)
5.0B
4.0B
3.0B
2.0B
1.0B
0
2.200 B
2025
2.497 B
2026
2.834 B
2027
3.217 B
2028
3.651 B
2029
4.144 B
2030
4.703 B
2031
Metric
2025
2026
2033
CAGR
U.S. Market Size
$2.20 Billion
$2.49 Billion
$6.01 Billion
13.5%
Global Market Size
$5.30 Billion
$6.00 Billion
$14.50 Billion
13.5%
U.S. Share of Global
41.4%
41.5%
41.4%
—
Screening and early detection commands 44.9% of U.S. applications revenue, driven by PSA reflex algorithms and PHI adoption.
Protein biomarkers dominate with 57.4% type share, led by PSA, PHI, and PCA3 protein assays.
Hospitals and diagnostic laboratories represent 63.0% of end-use revenue.
Protein Biomarkers and Genomic Assays in Early Detection
The U.S. biomarker landscape is anchored by protein biomarkers (PSA, Prostate Health Index, 4Kscore) that remain the clinical front line for screening. Genomic biomarkers—PCA3, TMPRSS2-ERG, and SelectMDx—are rapidly gaining traction for risk stratification and reducing unnecessary biopsies.
Biomarker Class
Examples
Share of U.S. Market (2025)
Primary Clinical Use
Protein
PSA, PHI, 4Kscore
57.4%
Screening, monitoring
Genetic
PCA3, TMPRSS2-ERG, BRCA2
24.1%
Risk stratification, prognosis
Cell-based
CTCs, cfDNA
12.8%
Treatment monitoring, liquid biopsy
Metabolomic
Sarcosine, citrate
5.7%
Aggressiveness discrimination
TMPRSS2-ERG fusion assays have been validated in Phase II trials (NCT01576172, 148 mCRPC patients) for recurrence prediction.
AR-V7 testing in castrate-resistant prostate cancer reached Phase III (NCT02438007, 953 patients), supporting therapy selection.
Cell-free DNA and circulating tumor cells are being evaluated in over 10 U.S.-based clinical trials for real-time monitoring.
Companion Diagnostics and Precision Oncology Uptake
The companion diagnostics segment is the fastest-growing application, expanding at a 15.2% CAGR through 2033. This growth is propelled by PARP inhibitor approvals (e.g., olaparib for BRCA-mutated mCRPC) and the emergence of AR-V7 and PTEN/PI3K/AKT pathway assays.
BRCA2 testing is now routine in metastatic prostate cancer, with Phase III trials (NCT03075735, 408 patients; NCT02987543, 387 patients) demonstrating clinical utility.
PTEN/PI3K/AKT/mTOR biomarker panels are in Phase II/III trials (NCT02573636, 208 high-risk patients; NCT03580239, 120 CRPC patients).
AI-enabled multi-omics platforms are integrating genomics, proteomics, and metabolomics to improve diagnostic precision and therapy matching.
Liquid Biopsy and Minimally Invasive Monitoring Expansion
Liquid biopsy is transforming U.S. prostate cancer management by enabling serial monitoring without tissue biopsy. Our interviews indicate that cfDNA and CTC assays are being adopted in 27% of academic centers and 11% of community oncology practices as of 2025.
Cell-free DNA trials (NCT00134056, 1,038 metastatic patients; NCT02853097, 300 metastatic patients) support real-time disease tracking.
Liquid biopsy reduces repeat biopsy costs by an estimated $1,200–$1,800 per patient, improving payer acceptance.
Hospital Laboratories and Biopharma End-Use Dynamics
Hospitals and diagnostic laboratories dominate end-use with 63.0% of revenue, followed by academic and research institutes (22.1%) and biopharmaceutical companies (14.9%).
U.S. hospital labs are investing in automated PHI and 4Kscore platforms to reduce turnaround time from 5 days to 48 hours.
Biopharma companies are embedding biomarker testing in 68% of prostate cancer clinical trials to enrich patient populations.
Academic centers drive early validation; NCI-designated cancer centers account for 41% of published prostate biomarker studies.
Reimbursement Variability and Advanced Assay Cost Barriers
The high cost of advanced biomarker testing—ranging from $300 to $4,500 per assay—and uneven Medicare coverage restrain broader adoption.
Reimbursement variability: Only 58% of U.S. private payers cover PHI testing; PCA3 coverage is 44%.
Regulatory complexity: CLIA and FDA pathways create 12–18 month delays for novel assays.
Sample handling inconsistencies (e.g., PSA degradation) reduce test accuracy by up to 15%, undermining clinical trust.
Competitive Landscape and Biomarker Validation Benchmarking
The U.S. market is moderately concentrated, with the top five players holding 48% of revenue. Key participants include Abbott, Beckman Coulter, Bio-Techne, Exact Sciences, Genomic Health, GenPath Oncology, MDxHealth, Myriad Genetics, OPKO Health, and Veracyte.
Company
Key Assay/Platform
U.S. Market Position
OPKO Health
4Kscore
Leader in protein biomarker panels
Myriad Genetics
Prolaris
Genomic risk stratification
MDxHealth
SelectMDx
Urine-based early detection
Exact Sciences
Oncotype DX GPS
Genomic recurrence prediction
Veracyte
Decipher
Post-surgical risk assessment
January 2025: OncoAssure Prostate biopsy-based test clinically validated for recurrence risk (BJUI Compass).
March 2026: Illumina–Labcorp collaboration to expand precision oncology testing access, including prostate biomarkers.
December 2025: Lunit–Daiichi Sankyo partnership integrating AI-powered digital pathology for biomarker discovery.
Us Prostate Cancer Biomarkers Market Report REPORT HIGHLIGHTS
Aspects
Details
Study Period
2020-2034
Base Year
2025
Estimated Year
2026
Forecast Period
2026-2034
Historical Period
2020-2025
Growth Rate
CAGR of 13.5% from 2020-2034
Segmentation
By Type
Genetic Biomarkers
Protein Biomarkers
Cell-based Biomarkers
Metabolomic Biomarkers
By Application
Screening and Early Detection
Diagnosis and Risk Stratification
Prognosis and Treatment Monitoring
Companion Diagnostics
By End Use
Hospitals and Diagnostic Laboratories
Academic and Research Institutes
Biopharmaceutical Companies
By Geography
United States
Northeast
Midwest
South
West
Table of Contents
1. Us Prostate Cancer Biomarkers Market Report Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Objective
1.4. Definitions and Assumptions
2. Us Prostate Cancer Biomarkers Market Report Executive Summary
2.1. Market Snapshot
3. Us Prostate Cancer Biomarkers Market Report Market Dynamics
3.1. Introduction
3.2. Market Drivers
3.2.1. Rising incidence of prostate cancer in the U.S.
3.2.2. Growing adoption of precision diagnostics and personalized medicine, Advancements in genomic, proteomic, and metabolomic technologies
3.2.3. Increasing clinical trial activity for biomarker validation
3.3. Market Restrains
3.3.1. High cost of advanced biomarker testing ($300–$4, 500 per assay)
3.3.2. Reimbursement variability across private and public payers
3.3.3. Regulatory complexity and delays for novel assay approval
3.3.4. Sample handling and standardization inconsistencies
3.4. Market Trends
3.4.1. Shift toward liquid biopsy and minimally invasive monitoring
3.4.2. Integration of AI and multi-omics in biomarker discovery
3.4.3. Growth of companion diagnostics for PARP inhibitors
3.4.4. Expansion of genomic risk stratification assays (Prolaris, Decipher)
4. Us Prostate Cancer Biomarkers Market Report Market Factor Analysis
4.1. Porters Five Forces
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. PESTEL analysis
4.3. BCG Analysis
4.3.1. Stars (High Growth, High Market Share)
4.3.2. Cash Cows (Low Growth, High Market Share)
4.3.3. Question Mark (High Growth, Low Market Share)
4.3.4. Dogs (Low Growth, Low Market Share)
4.4. Ansoff Matrix Analysis
4.5. Supply Chain Analysis
4.6. Regulatory Landscape
4.7. Current Market Potential and Opportunity Assessment (TAM–SAM–SOM Framework)
4.8. IDI Analyst Note
5. Us Prostate Cancer Biomarkers Market Report Market Analysis, Insights and Forecast, 2020-2034
5.1. Market Analysis, Insights and Forecast - by Type
5.1.1. Genetic Biomarkers
5.1.2. Protein Biomarkers
5.1.3. Cell-based Biomarkers
5.1.4. Metabolomic Biomarkers
5.2. Market Analysis, Insights and Forecast - by Application
5.2.1. Screening and Early Detection
5.2.2. Diagnosis and Risk Stratification
5.2.3. Prognosis and Treatment Monitoring
5.2.4. Companion Diagnostics
5.3. Market Analysis, Insights and Forecast - by End Use
5.3.1. Hospitals and Diagnostic Laboratories
5.3.2. Academic and Research Institutes
5.3.3. Biopharmaceutical Companies
5.4. Market Analysis, Insights and Forecast - by Region
5.4.1. United States
6. Us Prostate Cancer Biomarkers Market Report Competitive Analysis
6.1. Company Profiles
6.1.1. Abbott
6.1.1.1. Company Overview
6.1.1.2. Products
6.1.1.3. Company Financials
6.1.1.4. SWOT Analysis
6.1.2. Beckman Coulter Inc.
6.1.2.1. Company Overview
6.1.2.2. Products
6.1.2.3. Company Financials
6.1.2.4. SWOT Analysis
6.1.3. Bio-Techne
6.1.3.1. Company Overview
6.1.3.2. Products
6.1.3.3. Company Financials
6.1.3.4. SWOT Analysis
6.1.4. DiaCarta
6.1.4.1. Company Overview
6.1.4.2. Products
6.1.4.3. Company Financials
6.1.4.4. SWOT Analysis
6.1.5. Exact Sciences Corporation
6.1.5.1. Company Overview
6.1.5.2. Products
6.1.5.3. Company Financials
6.1.5.4. SWOT Analysis
6.1.6. ExoDx
6.1.6.1. Company Overview
6.1.6.2. Products
6.1.6.3. Company Financials
6.1.6.4. SWOT Analysis
6.1.7. Genomic Health
6.1.7.1. Company Overview
6.1.7.2. Products
6.1.7.3. Company Financials
6.1.7.4. SWOT Analysis
6.1.8. GenPath Oncology
6.1.8.1. Company Overview
6.1.8.2. Products
6.1.8.3. Company Financials
6.1.8.4. SWOT Analysis
6.1.9. MDxHealth
6.1.9.1. Company Overview
6.1.9.2. Products
6.1.9.3. Company Financials
6.1.9.4. SWOT Analysis
6.1.10. Myriad Genetics Inc.
6.1.10.1. Company Overview
6.1.10.2. Products
6.1.10.3. Company Financials
6.1.10.4. SWOT Analysis
6.1.11. Nucleix
6.1.11.1. Company Overview
6.1.11.2. Products
6.1.11.3. Company Financials
6.1.11.4. SWOT Analysis
6.1.12. OPKO Health Inc.
6.1.12.1. Company Overview
6.1.12.2. Products
6.1.12.3. Company Financials
6.1.12.4. SWOT Analysis
6.1.13. Proteomedix
6.1.13.1. Company Overview
6.1.13.2. Products
6.1.13.3. Company Financials
6.1.13.4. SWOT Analysis
6.1.14. Veracyte Inc.
6.1.14.1. Company Overview
6.1.14.2. Products
6.1.14.3. Company Financials
6.1.14.4. SWOT Analysis
6.1.15. Arquer Diagnostics
6.1.15.1. Company Overview
6.1.15.2. Products
6.1.15.3. Company Financials
6.1.15.4. SWOT Analysis
6.2. Market Entropy
6.2.1. Company's Key Areas Served
6.2.2. Recent Developments
6.3. Company Market Share Analysis, 2026
6.3.1. Top 5 Companies Market Share Analysis
6.3.2. Top 3 Companies Market Share Analysis
6.4. List of Potential Customers
7. Us Prostate Cancer Biomarkers Market Report Research Methodology
List of Figures
Figure 1: Us Prostate Cancer Biomarkers Market Report Revenue Breakdown (Billion, %) by Product 2026 & 2034
Figure 2: Us Prostate Cancer Biomarkers Market Report Value Share (%), by Type 2026 & 2034
Figure 3: Us Prostate Cancer Biomarkers Market Report Value Share (%), by Application 2026 & 2034
Figure 4: Us Prostate Cancer Biomarkers Market Report Value Share (%), by End Use 2026 & 2034
Figure 5: Us Prostate Cancer Biomarkers Market Report Share (%) by Company 2026
List of Tables
Table 1: Us Prostate Cancer Biomarkers Market Report Revenue Billion Forecast, by Type 2020 & 2034
Table 2: Us Prostate Cancer Biomarkers Market Report Revenue Billion Forecast, by Application 2020 & 2034
Table 3: Us Prostate Cancer Biomarkers Market Report Revenue Billion Forecast, by End Use 2020 & 2034
Table 4: Us Prostate Cancer Biomarkers Market Report Revenue Billion Forecast, by Region 2020 & 2034
Table 5: United States Us Prostate Cancer Biomarkers Market Report Revenue Billion Forecast, by Type 2020 & 2034
Table 6: United States Us Prostate Cancer Biomarkers Market Report Revenue Billion Forecast, by Application 2020 & 2034
Table 7: United States Us Prostate Cancer Biomarkers Market Report Revenue Billion Forecast, by End Use 2020 & 2034
Table 8: United States Us Prostate Cancer Biomarkers Market Report Revenue Billion Forecast, by Country 2020 & 2034
Table 9: Northeast Us Prostate Cancer Biomarkers Market Report Revenue (Billion) Forecast, by Application 2020 & 2034
Table 10: Midwest Us Prostate Cancer Biomarkers Market Report Revenue (Billion) Forecast, by Application 2020 & 2034
Table 11: South Us Prostate Cancer Biomarkers Market Report Revenue (Billion) Forecast, by Application 2020 & 2034
Table 12: West Us Prostate Cancer Biomarkers Market Report Revenue (Billion) Forecast, by Application 2020 & 2034
Research Methodology & Data Sources
Our rigorous research methodology combines multi-layered approaches with comprehensive quality assurance, ensuring precision, accuracy, and reliability in every market analysis.
Primary Research
70–80% primary research conducted through 42 in-depth interviews with U.S. stakeholders: hospital laboratory directors, diagnostic assay manufacturers, biopharma biomarker leads, and oncology clinicians.
Company types interviewed: (1) protein biomarker assay OEMs, (2) genomic/molecular diagnostic developers, (3) liquid biopsy platform providers, (4) biopharmaceutical companion diagnostics teams, (5) hospital and reference laboratory procurement heads.
Stakeholder titles: Director of Molecular Pathology, Vice President of Diagnostic Development, Clinical Biomarker Lead, and Chief of Urology/Oncology.
Industry associations and regulatory bodies referenced: College of American Pathologists (CAP), Clinical and Laboratory Standards Institute (CLSI), U.S. Food and Drug Administration (FDA), and National Comprehensive Cancer Network (NCCN).
Key Stakeholders Interviewed
Key Stakeholders Interviewed
Stakeholder Role
Interview Share (%)
Director of Molecular Pathology
30%
VP of Diagnostic Development
25%
Clinical Biomarker Lead
25%
Chief of Urology/Oncology
20%
Industry Ecosystem Breakdown
Industry Ecosystem Breakdown
Company Type
Representation (%)
Protein Biomarker Assay OEMs
25%
Genomic/Molecular Diagnostic Developers
20%
Liquid Biopsy Platform Providers
15%
Biopharma Companion Diagnostics Teams
20%
Hospital & Reference Laboratory Procurement
20%
Secondary Research & Industry Benchmarking
20–30% secondary research drawing from peer-reviewed journals (BJUI Compass, Journal of Clinical Oncology), clinical trial registries (ClinicalTrials.gov), and official government databases (National Cancer Institute SEER, CDC).
Financial databases: Bloomberg, Factiva, Hoovers, and PitchBook for company-level revenue and investment data.
Guaranteed estimated data accuracy level of 85–90%, validated through multi-level data triangulation.
Demand Modeling & Market Estimation
Top-down and bottom-up methodologies used simultaneously.
Bottom-up metrics: (1) annual PSA/PHI test volumes by U.S. laboratory, (2) average selling price per assay, (3) biomarker adoption rate in prostate cancer clinical trials, and (4) reimbursement coverage percentage by payer type.
Multi-level data triangulation: cross-validated bottom-up estimates against top-down national cancer screening expenditure and clinical trial biomarker spend.
Every report is updated to the date of purchase with the latest trial and reimbursement data.
Data Accuracy & Quality Check
Three-tier validation: primary interview trans scripts reviewed by senior analysts, secondary data cross-checked against government registries, and final estimates stress-tested against historical market growth.
Accuracy guarantee of 85–90% with a confidence interval of ±5% at the 95% confidence level.
Quality assurance: all sources verified for recency (2024–2026) and methodological rigor; no commercial market research firm data used.
Frequently Asked Questions
1. What is the size of the U.S. prostate cancer biomarkers market?
The U.S. prostate cancer biomarkers market was valued at $2.20 billion in 2025 and is projected to reach $6.01 billion by 2033, growing at a 13.5% CAGR from 2026 to 2033.
2. Which biomarker type dominates the U.S. prostate cancer biomarkers market?
Protein biomarkers, including PSA and Prostate Health Index (PHI), accounted for 57.4% of the U.S. market in 2025, supported by their established clinical validation and widespread screening use.
3. What is the fastest-growing application segment in the U.S. market?
Companion diagnostics is the fastest-growing application segment, expanding at a 15.2% CAGR through 2033, driven by PARP inhibitor approvals and precision oncology adoption.
4. Who are the key players in the U.S. prostate cancer biomarkers market?
Key players include Abbott, Beckman Coulter, Bio-Techne, Exact Sciences, Genomic Health, GenPath Oncology, MDxHealth, Myriad Genetics, OPKO Health, and Veracyte.
5. What are the main challenges in the U.S. prostate cancer biomarkers market?
High costs of advanced biomarker testing ($300–$4,500 per assay) and reimbursement variability—only 58% of private payers cover PHI testing—are significant restraints.
.jpg){kind=small}
